GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celadon Pharmaceuticals PLC (LSE:CEL) » Definitions » Tax Provision

Celadon Pharmaceuticals (LSE:CEL) Tax Provision : €0.30 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Celadon Pharmaceuticals Tax Provision?

Celadon Pharmaceuticals's tax provision for the six months ended in Dec. 2023 was €0.29 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2023 was €0.30 Mil.


Celadon Pharmaceuticals Tax Provision Historical Data

The historical data trend for Celadon Pharmaceuticals's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celadon Pharmaceuticals Tax Provision Chart

Celadon Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Tax Provision
- - 0.02 0.81 0.30

Celadon Pharmaceuticals Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Tax Provision Get a 7-Day Free Trial 0.02 - 0.81 0.01 0.29

Celadon Pharmaceuticals Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Celadon Pharmaceuticals (LSE:CEL) Business Description

Traded in Other Exchanges
N/A
Address
32-33 Cowcross Street, London, GBR, EC1M 6DF
Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis.

Celadon Pharmaceuticals (LSE:CEL) Headlines

No Headlines